Company Profile for Inflection Biosciences Ltd
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com.
|Company:||Inflection Biosciences Ltd|
Suite 15, Anglesea House, Carysfort Avenue,
|Type of Organization:||Private|
|Key Executives:||CEO: Darren Cunningham|
|Director of R&D: Michael O'Neill|
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005653/en/